Hepatitis C in transplant recipients of solid organs, other than liver

Area of Science:

• Hepatology
• Transplant Surgery
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection is common in solid organ transplant candidates and recipients.
• HCV negatively affects long-term patient and allograft survival, particularly in kidney transplant recipients.
• Outcomes for HCV in recipients of other solid organs (lung, heart, small bowel, pancreas) remain largely undefined.

Purpose of the Study:

• To review the impact of Hepatitis C virus infection on solid organ transplant recipients.
• To evaluate the efficacy and safety of interferon therapy for HCV in the context of organ transplantation.
• To provide recommendations for managing HCV in transplant candidates and recipients.

Main Methods:

• Literature review of prospective studies and clinical data.
• Analysis of patient and allograft survival rates in relation to HCV status.
• Assessment of outcomes associated with pre- and post-transplant interferon therapy.

Main Results:

• HCV infection is associated with reduced long-term survival in kidney transplant recipients.
• Pre-transplant interferon therapy for HCV can enhance outcomes.
• Post-transplant interferon therapy carries a risk of acute allograft rejection and is generally contraindicated, except in cases of advanced liver disease.

Conclusions:

• HCV screening and pre-transplant interferon therapy should be standard considerations for organ transplant candidates.
• Careful management is required to mitigate risks associated with HCV in transplant recipients.
• Further large-scale prospective studies are necessary to fully elucidate HCV outcomes in diverse solid organ transplant populations.